Clinical Trials Logo
  1. Home
  2. Healthy Male Subjects
  3. NCT03770039
  4. Details
NCT03770039 Clinical Trial

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects Clinical Trial

Official title:
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C-PF-06700841] AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06700841 IN HEALTHY MALE SUBJECTS USING A 14C-MICROTRACER APPROACH

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03770039
Other study ID # B7931014
Secondary ID 2018-002403-34
Status Completed
Phase Phase 1
First received
Last updated
Start date December 10, 2018
Est. completion date February 21, 2019

Study information
Verified date March 2019
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract

Recruitment information / eligibility
Status Completed
Enrollment 6
Est. completion date February 21, 2019
Est. primary completion date February 21, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Exclusion Criteria:

- Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).

- Total 14C radioactivity measured in plasma exceeding 11 mBq/mL

- History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test

- Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test

- Use of herbal supplements within 28 days prior to the first dose of study medication

- Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer

- Inability to have at least one bowel movement every 2 days on average eGFR of <90 mL/mim/1.73 m2 based on MDRD equation

- Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Oral PF-06700841 containing 14C microtracer
Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
• Oral unlabeled PF-06700841
60 mg unlabeled PF-06700841 oral dose in 2nd period
• IV 14C-labeled PF-06700841
30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

Locations
Country Name City State
Netherlands PRA Health Sciences Groningen
Netherlands PRA Health Sciences Utrecht Utrecht

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Netherlands, 

Outcome
Type Measure Description Time frame Safety issue
Primary mass balance_urine cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered hour 0 up to 312 hours post dose
Primary mass balance_feces cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered hour 0 up to 312 hours post dose
Secondary metabolite identification_plasma metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma Cmax for total 14C radioactivity maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma Tmax for total 14C radioactivity time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma AUClast for total 14C radioactivity area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma AUCinf for total 14C radioactivity area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary Oral clearance for total 14C radioactivity oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma half-life for total 14C radioactivity half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary volume of distribution for total 14C radioactivity apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary plasma Cmax for PF-06700841 maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma Tmax for PF-06700841 time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma AUClast for PF-06700841 area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma AUCinf for PF-06700841 area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary Oral clearance for PF-06700841 oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma half-life for PF-06700841 half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary volume of distribution for PF-06700841 apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma Cmax for 14C-labeled PF-06700841 maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma Tmax for 14C-labeled PF-06700841 time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma AUClast for 14C-labeled PF-06700841 area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma AUCinf for 14C-labeled PF-06700841 area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary clearance for 14C-labeled PF-06700841 clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary plasma half-life for 14C-labeled PF-06700841 half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary volume of distribution for 14C-labeled PF-06700841 volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841 hour 0 up to 96 hours post dose
Secondary unchanged PF-06700841 recovered in urine percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841 hour 0 up to 96 hours post dose
Secondary renal clearance of PF-06700841 renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841) hour 0 up to 96 hours post dose
Secondary Bioavailability of oral PF-06700841 Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841 hour 0 up to 96 hours post dose
Secondary Fraction absorbed of oral PF-06700841 Fraction absorbed in gut (Fa) following oral dose of PF-06700841 hour 0 up to 144 hours post dose
Secondary metabolite identification_urine metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
Secondary metabolite identification_feces metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841 hour 0 up to 312 hours post dose
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Completed NCT04655872 - Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects Phase 1
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT04839744 - A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT03576651 - A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1

External Links